ALK and cancer: Furthermore, we identified GSTP1 as a promising treatment target of LUAD not only through evidences of in vitro and in vivo GSTP1‐KD studies, but also by in vivo results of an ALK‐translocated cancer organoid model employing the FDA‐approved drug ezatiostat as a single agent or in combination with targeted therapy.